Sumitomo Pharma Co., Ltd.
SMDPY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $398,832 | $314,558 | $555,544 | $560,035 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Cost of Goods Sold | $153,437 | $126,577 | $178,919 | $157,127 |
| Gross Profit | $245,395 | $187,981 | $376,625 | $402,908 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| R&D Expenses | $49,865 | $112,637 | $131,858 | $94,903 |
| G&A Expenses | $180,605 | $429,538 | $279,355 | $179,559 |
| SG&A Expenses | $180,605 | $429,538 | $339,212 | $217,339 |
| Sales & Mktg Exp. | $0 | $0 | $59,857 | $37,780 |
| Other Operating Expenses | -$13,879 | $0 | -$17,466 | $30,432 |
| Operating Expenses | $216,591 | $542,175 | $453,604 | $342,674 |
| Operating Income | $28,804 | -$354,194 | -$76,979 | $60,234 |
| % Margin | 7.2% | -112.6% | -13.9% | 10.8% |
| Other Income/Exp. Net | -$11,193 | $31,745 | $29,059 | $22,727 |
| Pre-Tax Income | $17,611 | -$323,114 | -$47,920 | $82,961 |
| Tax Expense | -$6,024 | -$8,185 | $48,794 | $42,361 |
| Net Income | $23,634 | -$314,969 | -$74,512 | $56,413 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| Weighted Avg Shares Out | 397 | 397 | 397 | 397 |
| Weighted Avg Shares Out Dil | 397 | 397 | 397 | 397 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,307 | $36,022 | $32,218 | $25,777 |
| Interest Expense | $13,500 | $4,277 | $3,159 | $3,050 |
| Depreciation & Amortization | $25,562 | $37,765 | $41,263 | $38,348 |
| EBITDA | $56,673 | -$281,072 | -$3,498 | $124,359 |
| % Margin | 14.2% | -89.4% | -0.6% | 22.2% |